Plasma Concentrations of Rosmarinic Acid in Patients on Antiretroviral Therapy: In Silico Exploration Based on Clinical Data.
Maja HitlNebojša PavlovićSnežana BrkićGordana DragovićBranislava Srđenović ČonićNebojša KladarPublished in: International journal of molecular sciences (2024)
Rosmarinic acid (RA) is a phenolic compound with antiviral properties, often encountered in dietary supplements and herbal drugs. Data on the pharmacokinetics of RA are lacking in cases of the chronic use of supplements containing this compound, and only limited data on the metabolism and distribution of RA are available. The aim of the study was to investigate the plasma levels of RA after 12 weeks of use and determine potential interactions of RA and selected antiretroviral drugs. Patients infected with human immunodeficiency virus took a supplement containing RA for 12 weeks, after which the RA concentrations in the plasma samples were analyzed. A detailed in silico analysis was conducted in order to elucidate the potential interactions between RA and the drugs efavirenz, darunavir and raltegravir. It was found that RA can be detected in patients' plasma samples, mainly in the form of sulphoglucuronide. The potential interactions are suggested on the level of liver metabolizing enzymes and efflux P-glycoprotein, with RA competing with antiretroviral drugs as a substrate in metabolism and distribution systems. The present study suggests that the simultaneous use of RA and antiretroviral therapy (containing efavirenz, darunavir or raltegravir) may affect the plasma levels of RA after prolonged supplementation.
Keyphrases
- rheumatoid arthritis
- antiretroviral therapy
- human immunodeficiency virus
- hiv infected patients
- hiv infected
- disease activity
- end stage renal disease
- ankylosing spondylitis
- hiv aids
- newly diagnosed
- chronic kidney disease
- interstitial lung disease
- peritoneal dialysis
- hepatitis c virus
- machine learning
- big data
- systemic lupus erythematosus
- human health
- drug induced
- molecular dynamics simulations
- climate change
- idiopathic pulmonary fibrosis